The Australian government has given a funding boost to an Australian biomedical research organisation, the Garvan Institute of Medical Research, to conduct clinical trials for the world’s first gene therapy for type 1 diabetes.
The therapy was also developed thanks to the government’s ten-year $600 million (US$385 million) research accelerator program, targeted at addressing chronic and complex diseases.
